CD274 and acute kidney injury: The incidence of ICI–associated acute kidney injury (AKI) is estimated to range from 1.4% to 4.9%, with dual ICI regimens carrying an increased risk when compared with monotherapy with anti-CTLA-4, anti-PD-1, or anti-PD-L1 (17–20).